Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Current Deferred Revenue (2016 - 2018)

Historic Current Deferred Revenue for Heron Therapeutics (HRTX) over the last 4 years, with Q4 2018 value amounting to $14.0 million.

  • Heron Therapeutics' Current Deferred Revenue rose 40705.75% to $14.0 million in Q4 2018 from the same period last year, while for Dec 2018 it was $14.0 million, marking a year-over-year increase of 40705.75%. This contributed to the annual value of $14.0 million for FY2018, which is 40705.75% up from last year.
  • Latest data reveals that Heron Therapeutics reported Current Deferred Revenue of $14.0 million as of Q4 2018, which was up 40705.75% from $10.5 million recorded in Q3 2018.
  • In the past 5 years, Heron Therapeutics' Current Deferred Revenue ranged from a high of $14.0 million in Q4 2018 and a low of $1.1 million during Q4 2016
  • Its 3-year average for Current Deferred Revenue is $6.2 million, with a median of $5.2 million in 2017.
  • Over the last 5 years, Heron Therapeutics' Current Deferred Revenue had its largest YoY gain of 40705.75% in 2018, and its largest YoY loss of 5520.53% in 2018.
  • Heron Therapeutics' Current Deferred Revenue (Quarter) stood at $1.1 million in 2016, then skyrocketed by 151.41% to $2.8 million in 2017, then surged by 407.06% to $14.0 million in 2018.
  • Its last three reported values are $14.0 million in Q4 2018, $10.5 million for Q3 2018, and $9.4 million during Q2 2018.